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Abstract
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Aims—Epigenetic regulators, including microRNAs(miRNAs), are implicated in type 2 diabetes,
but evidence linking circulating miRNAs in pregnancy and risk of gestational diabetes(GDM) is
sparse. Potential modifiers, including pre-pregnancy overweight/obesity and offspring sex, are
unexamined. We hypothesized that circulating levels of early-mid-pregnancy(range 7-23 weeks of
gestation) candidate miRNAs are related to subsequent development of GDM. We also
hypothesized that miRNA-GDM associations might vary by pre-pregnancy body-mass
index(ppBMI) or offspring sex.
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Methods—In a case-control analysis(36 GDM cases/80 controls) from the Omega study, a
prospective cohort study of pregnancy complications, we measured early–mid-pregnancy plasma
levels of 10 miRNAs chosen for potential roles in pregnancy course and
complications(miR-126-3p, -155-5p, -21-3p, -146b-5p, -210-3p, -222-3p, -223-3p, -517-5p,
-518a-3p, and 29a-3p) using qRT-PCR. Logistic regression models adjusted for gestational age at
blood draw (GA) were fit to compare circulating miRNAs between cases and controls. We
repeated analyses among overweight/obese(ppBMI≥25kg/m2) or lean(ppBMI<25kg/m2) women,
and women with male or female offspring separately.
Results—Mean age was 34.3 years(cases) and 32.9 years(controls). GA-adjusted
miR-155-5p(β=0.260/p=0.028) and - 21-3p(β=0.316/p=0.005) levels were positively associated
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with GDM. MiR-146b-5p(β=0.266/p=0.068) and miR-517-5p(β=0.196/p=0.074) were borderline.
Associations of miR-21-3p and miR-210-3p with GDM were observed among overweight/obese
but not lean women. Associations of six miRNAs(miR-155-5p, -21-3p, - 146b-5p, -223-3p,
-517-5p, and -29a-3p) with GDM were present only among women carrying male fetuses(all
p<0.05).
Conclusions—Circulating early–mid-pregnancy miRNAs are associated with GDM, particularly
among women who are overweight/obese pre-pregnancy or pregnant with male offspring. This
area has potential to clarify mechanisms underlying GDM pathogenesis and identify at-risk
mothers earlier in pregnancy.
Keywords
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1. Introduction

Author Manuscript

Gestational diabetes (GDM) is increasingly common, affecting 5-15% of pregnancies[1],
and is implicated in adverse outcomes for both mother and child[2]. Controversy persists
surrounding GDM screening, but current consensus recommendations support screening for
GDM in mid pregnancy (24-28 weeks gestation)[3]. Changes related to maternal glycemia
and fetal hyperinsulinemia, however, begin much earlier[4, 5]. The pathophysiology of
GDM is not completely understood, and early-mid pregnancy biomarkers may facilitate
progress in this area. Early-mid pregnancy biomarkers could help in investigations of
mechanisms that define the role of well-known risk factors, such as pre-pregnancy
overweight/obesity status, and novel risk factors, such as fetal sex, in GDM pathogenesis.
For example, mothers of male offspring have been shown to have lower beta-cell function
(as reflected by the disposition index) and higher risk of GDM[6], but mechanisms
explaining these observations are unknown.
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MiRNAs are small non-coding RNAs (approximately 20 nucleotides in length) that regulate
gene expression and diverse cellular functions by directing degradation or inhibiting
translation of messenger RNA transcripts[7]. Differential miRNA expression has been
demonstrated in adipocytes, islet cells, endothelium, and hepatocytes, as well as smooth,
skeletal, and cardiac muscle cells[8-17] among type 2 diabetes (T2D) cases, compared with
controls. Identified miRNAs have been related to insulin secretion, inflammation, and
insulin resistance. Differences have also been seen in circulating levels of miRNAs (e.g.,
miR-126, -146a, and -29a) comparing type 2 diabetes (T2D) cases to controls[13, 18-27].
Epigenetic regulatory mechanisms, including miRNAs, may also have important roles in
GDM, a condition that shares similar pathophysiologic features to T2D[28-33]. Several
small studies have demonstrated differences in placental or umbilical vein endothelial cell
miRNA expression at delivery in GDM pregnancies vs. controls[28-33]. Only two previous
studies, however, have compared second-trimester circulating miRNA levels in women with
GDM to controls[34, 35]. These previous studies were small (n = 20 and n = 48) and were
limited to Asian populations. In addition, to our knowledge, no previous study has examined
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maternal pre-pregnancy overweight/obesity- or fetal–sex-specific associations of miRNAs
with GDM.
In the current study, we selected candidate miRNAs that have previously been associated
with pregnancy complications (e.g., GDM, preeclampsia, or intrauterine growth retardation)
or pathophysiologic pathways (e.g., placental functions, oxidative stress, and inflammation)
related to pregnancy complications.[23, 27, 34] We hypothesized that circulating levels of
early-mid- (7-23 weeks) pregnancy candidate miRNAs are related to subsequent
development of GDM. We also hypothesized that associations of these candidate miRNAs
with GDM might vary by pre-pregnancy overweight and obesity or by offspring sex.

2. Materials and Methods
2.1. Study setting and study population

Author Manuscript

The study was conducted among participants of the Omega study, a pregnancy cohort study
based at the Center for Perinatal Studies at Swedish Medical Center in Seattle, Washington.
Study design and protocols have been published previously[36]. Briefly, the Omega study
was designed to examine metabolic and dietary risk factors of preeclampsia, GDM, and
other pregnancy complications/outcomes. From 1996 to 2008, participants were recruited
from prenatal care clinics affiliated with Swedish Medical Center in Seattle and Tacoma
General Hospital in Tacoma, Washington.
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Pregnant women were eligible to participate in the Omega study if they were ≥18 years old
at enrollment, initiated prenatal care prior to 16 weeks of pregnancy, were able to speak and
read English, and planned to carry the pregnancy to term and deliver at one of the study
hospitals. During the study period, approximately 80% of eligible women who were
approached consented to participate and >95% were followed until delivery. Among 4,011
Omega study participants, a subcohort of 767 randomly selected participants was included in
a traffic-related air-pollution case-cohort study investigating course and complications of
pregnancy. For the current study, we included all GDM cases from the subcohort (n = 38)
and 100 randomly selected control participants without GDM, pre-eclampsia, low
birthweight, or preterm delivery. Participant characteristics for the subcohort were similar to
characteristics of the Omega study population (Table 1). Of the randomly selected controls,
17 were missing plasma samples. After excluding non-singleton pregnancies, we were left
with an analytic sample of 116 participants (36 GDM cases, 80 controls). Characteristics of
the participants with missing plasma samples were similar to those included in the current
study (Supplementary Table 1).
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The institutional review boards of Swedish Medical Center and Tacoma General Hospital
approved the study, and all study participants provided written informed consent.
2.2. Data collection
At an enrollment visit before 20 weeks of gestation, trained interviewers conducted inperson interviews (45-60 minutes in length) to collect data on expectant mothers' age,
height, pre-pregnancy weight, socioeconomic characteristics, reproductive and medical
histories, and tobacco consumption before and during pregnancy. Pre-pregnancy body mass
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index (ppBMI), based on self-reported measures of weight and height, was calculated as
weight in kg divided by height in meters squared. Expectant mothers with ppBMI≥25kg/m2
were classified as overweight/obese and were compared to women with ppBMI<25kg/m2 in
analyses of potential effect modification by overweight/obese status. Gestational weight gain
was calculated as the difference in weight between last recorded maternal weight within four
weeks prior to delivery (abstracted from medical records) and self-reported pre-pregnancy
weight during the three months prior to conception. Maternal race was classified as nonHispanic white, non-Hispanic black, Asian, Hispanic, or other. Maternal peripheral blood
was collected shortly after enrollment (see below). Mothers were followed through delivery,
and trained personnel abstracted data on course and outcomes of the pregnancy (e.g., GDM,
offspring sex) from maternal and infant medical records.
2.3. GDM diagnosis
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A 50g glucose challenge test was administered between gestational weeks 24 and 28 to
screen for GDM as part of routine follow-up of all women at participating clinics. Women
testing positive on the screening test (≥140 mg/dL) completed an additional 100g, three-hour
oral glucose tolerance test (OGTT) within two weeks of the first test. Women were
diagnosed with GDM if two or more plasma glucose values during the three-hour OGTT
exceeded the following American Diabetes Association (ADA) 2004 criteria cut-points:
fasting ≥ 95 mg/dL; 1-hr ≥ 180 mg/dL; 2-hr ≥ 155 mg/dL; or 3-hr ≥ 140 mg/dL[37].
2.4. Sample collection, pre-processing, and RNA extraction
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Peripheral blood samples, collected at 16.1 weeks of gestation on average (range 7.0-22.9),
were kept at 4°C until processing that occurred within 1 hour of collection. Approximately
200μL of plasma was used for extracting small RNAs using the Exiqon miRCURY™ RNA
Biofluids Isolation Kit (Exiqon, Woburn, MA). We assessed the integrity, purity, and
quantity of purified miRNA using spectrophotometry and an Agilent 2100 Bioanalyzer
capillary electrophoresis system (Agilent Technologies Inc, Palo Alto, CA). To further
assess quality of extracted RNA, we measured spike-in values of cel-miR-39.
2.5. miRNA selection, profiling, data processing, and normalization
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We chose the following miRNAs: miR-126-3p, -155-5p, -21-3p, -146b-5p, -210-3p, -222-3p,
-223-3p, -517-5p, -518a-3p, and -29a-3p. The selected candidate miRNAs have previously
been associated with type 2 diabetes (miR-126[27], -223[27], and -29a[24]); pregnancy
complications including pre-eclampsia (miR-155[38], -210[39], 517[40], and -518a[41]),
growth restriction (miR-21[42] and -517[40]), and GDM (miR-222[33]); or pathways
related to pregnancy complications including oxidative stress (miR-21[43]), endothelial
function (miR-126, -210, and -222[44]), or inflammation (miR-155[45] and -146b[46]). We
constructed a custom targeted panel of the candidate miRNAs and two control miRNA
assays using ExiqonLNA™ primers. An exogenous miRNA cel-miR-39 was added as a
positive control for technical factors including RNA extraction, complementary DNA
synthesis, and PCR amplification[47], as mentioned above, and an endogenous
“housekeeping” miRNA, miR-423-3p was chosen for normalization, based on previous
recommendations[48]. qPCR was conducted in duplicate using 96-well qPCR plates.
Reactions were run on an ABI PRISM 7000 Real Time PCR machine (Applied Biosystems,
Diabetes Res Clin Pract. Author manuscript; available in PMC 2018 October 01.
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Foster City, CA), using default cycling conditions. We recorded threshold cycle (CT) values
on two measurements per sample. True replicates were done in the sense that the original
plasma samples were split, completely independent RNA preps were done, independent RT
reaction was performed for each replicate, and each replicate was run on a different qPCR
96-well plate. CT values of the duplicates differing by greater than 0.2 times the standard
deviation were re-tested, and replicates were averaged for analyses. Lab personnel was
blinded to case-control status. Data from miRNA qRT-PCR arrays were imported into SDS
Enterprise Software (V2.2.2, Applied Biosystems), and CT values were calculated using a
consistent thresholding value for each assay across all plates. Raw CT values were scaled to
values for cel-miR-39-3p. Then, ΔΔCT values were expressed relative to values of
miR-423-3p and used in subsequent analyses.
2.6. Statistical analyses
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We examined distributions of selected characteristics, as well as gestational age at blood
draw, among GDM cases and controls. MiRNA CT values were log-transformed to achieve
normal distribution. We used parallel coordinates plots of ln(miRNA) levels to visualize
patterns of variability that might differ by case status. We then fit logistic regression models
examining the association of each candidate miRNA with GDM, adjusting for gestational
age at blood collection (Model 1), and adjusting for gestational age at blood collection,
maternal age, and pre-pregnancy BMI (Model 2). Because we hypothesized that associations
of circulating miRNA levels with GDM might differ by pre-pregnancy obesity or offspring
sex, we fit gestational-age-adjusted models that were stratified by pre-pregnancy overweight/
obesity or offspring sex. If there were differences in associations among strata, we fit models
that included terms for miRNAs, pre-pregnancy overweight/obesity status or offspring sex,
and an interaction term for pre-pregnancy obesity or offspring sex and miRNA, to assess
statistical significance of the interactions. We used Stata version 13.1 (College Station, TX),
R 3.3.1 (www.R-project.org), including the MASS package[49], and MATLAB Software
Package (The MathWorks Corporation, Natick, MA) for the analyses. All tests were twosided and p<0.05 was used to determine statistical significance.

3. Results
On average, GDM cases were 34.3 years old at enrollment, while controls were 32.9 years
old. Blood samples were collected at 15.1 weeks among cases and 16.5 weeks among
controls (Table 1). Cases had greater ppBMI on average than controls (median 25.5 kg/m2
vs. 21.7 kg/m2). Median values of untransformed miRNA CT levels are shown in Table 2.
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Parallel coordinates plots did not reveal systematic patterns of variability in miRNA
expression profiles by GDM case status (not shown). In models adjusted for gestational age
at blood collection, higher circulating levels of two miRNAs, miR-155-5p (β=0.260,
p=0.028) and -21-3p (β=0.316, p=0.005), were associated with higher odds of GDM. In
addition, associations of miR-146b-5p (β=0.266, p=0.068) and miR-517-5p (β=0.196,
p=0.074) with GDM odds were borderline. The associations were attenuated in models
adjusting for gestational age at blood draw, maternal age, and ppBMI; only miR-21-3p
(β=0.262, p=0.029) remained significantly associated with higher odds of GDM (Table 3).
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In analyses stratified by pre-pregnancy BMI category, associations between miRNA and
GDM risk were similar between overweight/obese and lean women, except for associations
of miR-21-3p and miR-210-3p with GDM risk. Associations of these two miRNAs,
miR-21-3p (β =0.467, p=0.042) and miR-210-3p (β=0.514, p=0.036), were observed only
among women who were overweight/obese during pre-pregnancy. In a logistic regression
model with interaction between obesity status and miRNA, the interaction term was not
significant for miR-21-3p and was borderline for miR-210-3p (Table 4). In stratified
analyses by the sex of the fetus, among participants who were pregnant with male offspring,
circulating levels of miR-155-5p (β=0.474, p=0.008), -21-3p (β=0.665, p=0.003),
miR-146b-5p (β=0.418, p=0.037), -223-3p (β=0.421, p=0.047), -517-5p (β=0.377,
p=0.028), and -29a-3p (β=0.345, p=0.047) were associated with risk of GDM (Table 5).
Among participants who were pregnant with female offspring, none of the candidate
circulating miRNAs were associated with risk of GDM. Tests for interaction effects between
miRNA and offspring sex were statistically significant for miR-21-3p (p=0.020) and
borderline (< 0.10) for several of the other miRNAs: miR-155-5p (p=0.059), -223-3p
(p=0.060), -517-5p (p=0.076), or 29a-3p (p=0.059).

4. Discussion
In this study, we found that early–mid-pregnancy maternal plasma levels of two miRNAs
(miR-155-5p and -21-3p) were associated with subsequent risk of GDM. Associations of
miR-21-3p, along with miR-210-3p, with GDM odds was observed only among women who
were overweight/obese prior to pregnancy. In sex-stratified analyses, associations of
miR-155-5p, -21-3p, and four others (miR-146b-5p, -223-3p, -517-5p, and -29a-3p) with
subsequent risk of GDM were present only among mothers bearing male offspring.
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Two previous studies have measured circulating miRNA levels in women with GDM and
controls[34, 35]. Zhao et al. compared serum miRNA levels at 16-19 weeks gestational age
among 24 GDM cases (based on 75-g OGTT results) and 24 controls using Taqman Low
Density array (human microRNA panel V2.0) and pooled samples, followed by
confirmatory qRT-PCR in the primary study population and two separate populations[34,
35]. In that study, GDM cases and controls were frequency matched for age, gestational age,
and pre-pregnancy BMI. Women older than 33 years or with BMI > 26kg/m2 were excluded.
They reported lower levels of miR-132, -222, and -29a among GDM cases compared with
controls. Zhu et al. performed a pilot study using high-throughput sequencing on pooled
plasma samples (collected at 16-19 weeks gestational age) from 10 GDM cases (based on
75-g OGTT results) and 10 age- and gestational-age–matched controls, followed by qRTPCR confirmatory experiments[34, 35]. In the sequencing study, twelve miRNAs were
upregulated and 20 were downregulated. On confirmatory qRT-PCR, five miRNAs
(miR-16-5p, -17-5p, -19a-3p, -19b-3p, and 20a-5p) were seen at higher levels in GDM
plasma, compared with controls. In our analysis, we did not see differences in miR-222 or
-29a levels between GDM case and control groups, although miR-29a was associated with
GDM risk in the analysis restricted to male offspring. We did not measure miR-192, nor the
miRNAs that were identified in Zhu's pilot study. To our knowledge, no previous study has
reported pre-pregnancy overweight/obesity- or offspring sex-specific associations of
miRNAs with GDM risk.
Diabetes Res Clin Pract. Author manuscript; available in PMC 2018 October 01.
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There are some important differences among 1) the populations studied, 2) the study
designs, and 3) the laboratory techniques that might explain the differing miRNAs identified
in ours and previous studies. For example, both previous studies were performed in Chinese
populations. The cohorts were also relatively younger and leaner than in the Omega study. In
the Zhu study, although women were not excluded based on age or ppBMI, on average,
GDM cases were younger (mean age 30 years) and leaner (mean ppBMI 24kg/m2) than our
population. Zhao excluded women 33 years or older or with BMI > 26kg/m2. In both
previous studies, samples were collected between 16 and 19 weeks. The authors did not
additionally adjust for gestational age at the time of blood draw, potentially a key factor, as
currently available evidence suggests that circulating miRNA levels may change across the
course of pregnancy[50, 51]. In addition to adjusting for gestational age in all models, we
also conducted a sensitivity analysis excluding participants with specimens collected at the
extremes of gestational age, with quantitatively very similar results. Previous authors also
did not comment on the prevalence of other pregnancy complications in their populations.
Our controls did not have preterm delivery (PTD), pre-eclampsia (PE), or low birthweight
(LBW). Of the GDM cases in our analytic sample, eight had one or more of these other
pregnancy complications. (Three had LBW. Two had PE, and five had PTD. Two
pregnancies had both LBW and PTD.) Pre-eclampsia and preterm delivery share common
risk factors and mechanisms with GDM[52], so we included GDM cases with PE or PTD in
our analytic sample. We conducted a sensitivity analysis excluding LBW cases, however.
Findings were similar to the primary results we have reported in this manuscript.

Author Manuscript

Differing pre-processing and normalization strategies may also have contributed importantly
to the varying results. Zhao normalized to spike-in levels of C. elegans miR-39[34, 35]. Zhu,
however, normalized to endogenous miR-221 level[34, 35]. Although miR-221 is sometimes
used for normalization, it has been related to inflammation[53], which has been linked to
abnormal glucose metabolism and diabetes[54]. Differences in pre-analytic strategies,
especially normalization, have been implicated as factors contributing to inconsistent results
seen in circulating miRNA-T2D association studies[55, 56]. We, therefore, conducted
multiple sensitivity analyses using two other normalization strategies: we normalized to celmiR-39 level only and also performed quantile normalization. In general, findings from our
sensitivity analyses were similar to the primary results we have reported in this manuscript
with one exception. MiR-155 was not associated with GDM in quantilenormalized analyses
using all participants, but it was associated with GDM when we restricted the quantilenormalized analysis to pregnancies with male fetuses only.
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Our study identified several candidate miRNAs that are associated with risk of GDM either
in overall analyses or analyses stratified by pre-pregnancy obesity or offspring sex. Several
of these miRNAs have previously been implicated in the pathogenesis of T2D. For example,
miR-29a is seen at higher levels in serum and whole blood of individuals with newly
diagnosed and existing T2D[24]. Overexpression of miR-29a also leads to insulin resistance
in adipocyte cell lines, possibly by targeting proteins in the PTEN-AKT pathway[57]. On
the other hand, Zampetaki et al. identified lower levels of both miR-21 and -223 when they
compared individuals with prevalent diabetes to controls[27]. miR-155 was also seen at
lower levels in peripheral blood mononuclear cells of individuals with diabetes compared to
controls[58], although in that sample, most of the patients with diabetes were treated with
Diabetes Res Clin Pract. Author manuscript; available in PMC 2018 October 01.
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metformin and/or a sulfonylurea, which may have influenced results. Several of the
candidates we identified (miR-155-5p, -21-3p, and -223-3p) are highly expressed in a
variety of tissues and have been associated with a number of malignant and non-malignant
disease states[59], suggesting they might play roles in regulatory pathways common across
cell types, including apoptosis, cell-cycle regulation, and response to inflammation. For
example, upregulation of miR-155 in both umbilical vein endothelial cells and placenta
tissues has been implicated in the pathogenesis of pre-eclampsia, possibly by inhibiting
trophoblast invasion and proliferation via the cell-cycle regulator Cyclin D1[60, 61].
miR-155 and -146b, also identified in our study, are induced by inflammatory cytokines,
including NF-κB[46, 62, 63]. In the case of miR-21, miR depletion in a pancreatic cancer
model led to increased apoptosis of malignant cells, inhibiting tumor growth[64]. In
pancreatic β-cells of mice with a model of T1D, NF-κB increased miR-21 levels, while
miR-21 decreased the level of PDCD4, an inducer of apotosis[65]. In contrast to these
widely expressed miRNAs, miR-517-5p is thought to be relatively specific to placenta. It has
been linked to development of pre-eclampsia, possibly by regulating trophoblast
proliferation[60]. Our findings support its potential role in GDM pathogenesis.
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In the current study, the statistically significant miRNA-GDM associations we observed
were limited to pregnancies in mothers with pre-pregnancy overweight or obesity. This may
be due in part to the candidate miRNAs we selected, which were reflective of pathways that
link obesity and Type 2 diabetes, highlighting potential differences in pathways that lead to
GDM among obese and lean women. Gestational weight gain in early pregnancy might also
influence the association of circulating miRNAs with GDM risk. In our dataset, ppBMI was
correlated with gestational weight gain in the first 20 weeks of pregnancy (Pearson
correlation coefficient -0.25, p=0.009). In a post-hoc analysis, we fit a model that adjusted
for early pregnancy gestational weight gain and observed no meaningfully different results
compared to the ones we report in this manuscript. It is also possible that overweight/obese
mothers differed from lean mothers in other characteristics (e.g., diet and socio-economic
status). Sample size limited our ability to fully account for these potential confounders.
Additionally, miRNA-GDM associations were observed among pregnancies with male
infants, but not female infants. Male fetal sex has been associated with both higher risk of
maternal GDM and a lower disposition index[6] in the mother, suggesting the association of
sex with GDM may be mediated in part by an effect of fetal sex on maternal beta-cell
function. Sex-specific differences in placental development, placental hormone secretion and
placental response to maternal factors have also been reported, including differences in
expression of immune-regulating genes[66], which may reflect differences in maternal
immune tolerance to the male fetus[67]. To the extent that these are related to risk of GDM,
they may explain, at least in part, the sex-specific differences in miRNA-GDM associations
that we observed. Placental miRNAs appear to regulate both trophoblast cell migration and
maternal immune response[67], which may occur in a sex-dependent fashion. For instance,
miR-517b, which was associated with GDM among pregnancies with male fetuses only,
regulates expression of TNFS15[68], a pro-inflammatory, anti-angiogenic cytokine, which
may reflect a sex-specific placental response to the maternal immune system. In line with
recent National Institutes of Health statements highlighting the growing awareness of
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differences in response to metabolic stressors by sex at all ages[69], future studies
investigating fetal–sex-specific effects of miRNAs in pregnancy are warranted.
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The current study has several strengths, most notably, the use of a well-characterized
prospective cohort of pregnant women and adjustment for gestational age at blood collection
—an important potential determinant of circulating miRNA levels[50, 51]. The fact that
associations remained generally consistent across normalization strategies also lends
credibility to our findings. Several limitations of the study deserve mention. First, we used a
candidate-miRNA approach, which might exclude important miRNAs related to GDM
pathogenesis. Our list of miRNAs was chosen based on thorough literature review, however,
and these candidate biomarkers had biologically plausible functions regulating messenger
RNA targets involved in putative cellular functions. Second, our study is of moderate size.
Larger studies will need to replicate these findings in a variety of populations. Third, we did
not assess downstream effects of the miRNAs we identified. Last, because we had a limited
number of non-white participants or participants with lower education levels or SES, results
may not be generalizable to more diverse populations. In a sensitivity analysis, we repeated
our analyses among non-Hispanic white mothers. While there were some differences in
specific estimates, in general, findings were similar to what was reported in the current
manuscript including the fact that associations were observed only among participants who
were overweight/obese pre-pregnancy or who were pregnant with male offspring.
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In sum, our findings suggest that early-mid–pregnancy circulating miRNAs are associated
with subsequent risk of GDM, particularly among women who were overweight/obese prior
to the pregnancy or among women bearing male offspring. Larger follow-up studies in
populations representative of a variety of ethnic groups and socio-economic backgrounds as
well as profiling of larger set of candidate miRNAs or epigenome-wide profiling (e.g., using
sequencing approaches) may clarify mechanisms underlying GDM pathogenesis as well as
potential pre-pregnancy overweight/obesity- or offspring-sex–specific differences. Better
mechanistic understanding of GDM pathogenesis may help identify mothers at high risk of
GDM earlier in pregnancy and guide development of targeted preventive interventions.
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Highlights
•

Evidence linking circulating miRNAs in pregnancy and risk of gestational
diabetes (GDM) is sparse.

•

Whether miRNA-GDM associations vary by pre-pregnancy body-mass index
or offspring sex is unknown.

•

Levels of circulating gestational age-adjusted miRNAs were associated with
GDM risk.

•

Associations varied by pre-pregnancy overweight/obesity and offspring sex.
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Author Manuscript
51 (1,903)

6 (217)

Offspring sex, % male (n)

Smoked during pregnancy, % (n)

86 (3,412)

Race, % white (n)
4 (153)

85 (3,404)

Married, % yes (n)

High school education or less, % (n)

38 (1,525)

Primiparous, % yes (n)

38.3 (4.0)

Mean gestational age at delivery, weeks
27 (1073)

16.0 (6.1)

Mean gestational weight gain**, kg (SD)

96 (3,807)

22.4 (4.6)

Median pre-pregnancy body-mass index, kg/m2 (Q1-Q3)

Singleton pregnancy, % yes (n)

15.6 (3.0)

Mean gestational age at blood draw, weeks (SD)

Overweight/obese, % yes (n)

32.6 (4.6)

Mean maternal age, years (SD)

Omega overall n=4,011

51 (373)

5 (39)

2 (18)

86 (655)

88 (675)

36 (279)

96 (733)

27 (210)

38.4 (3.3)

16.1 (6.0)

22.5 (4.6)

16.0 (2.6)

32.7 (4.4)

Environmental study subcohort n=767

p-value from t-test or chi-squared test comparing means or proportions among GDM cases and controls in the current study

*

Author Manuscript
Table 1

Author Manuscript
61 (22)

9 (3)

3 (1)

67 (24)

86 (31)

39 (14)

100 (36)

53 (19)

38.2 (1.7)

12.4 (7.8)

25.5 (6.7)

15.1 (2.9)

34.3 (3.6)

GDM cases n=36

50 (39)

8 (6)

3 (2)

80 (63)

86 (69)

34 (27)

100 (80)

16 (13)

38.9 (1.3)

15.9 (5.6)

21.7 (4.1)

16.5 (2.3)

32.9 (4.4)

Controls n=80

0.269

0.835

0.898

0.130

0.984

0.592

—

<0.0001

0.0196

0.001

0.0003

0.0098

0.101

p-value*

Baseline characteristics of Omega participants, environmental study subcohort participants, and gestational diabetes cases and controls in
the current study
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Table 2

Median* values of circulating candidate microRNAs

Author Manuscript

miR-126-3p (Q1-Q3)

GDM cases

Controls

1.0 (0.3-2.7)

0.8 (0.2-2.7)

miR-155-5p (Q1-Q3)

3.8 (0.8-13.4)

1.8 (0.4-4.9)

miR-21-3p (Q1-Q3)

12.2 (3.0-33.8)

3.4 (1.1-11.6)

miR-146b-5p (Q1-Q3)

3.9 (0.8-9.4)

1.4 (0.8-5.8)

miR-210-3p (Q1-Q3)

2.3 (0.7-4.6)

1.5 (0.3-3.9)

miR-222-3p (Q1-Q3)

1.2 (0.4-2.5)

1.1 (0.2-3.0)

miR-223-3p (Q1-Q3)

1.7 (0.5-2.7)

0.9 (0.3-3.3)

miR-517-5p (Q1-Q3)

5.2 (1.1-19.0)

2.7 (0.5-10.8)

miR-518a-3p (Q1-Q3)

6.1 (2.8-43.7)

5.1 (1.2-27.4)

miR-29a-3p (Q1-Q3)

1.0 (0.3-2.2)

0.7 (0.2-2.1)

Author Manuscript

*

cel-miR-39-adjusted ΔΔCt levels relative to housekeeping miR (miR-423-3p)

Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Author Manuscript

Author Manuscript

0.260

0.316

0.266

0.153

0.070

0.177

0.196

0.077

0.151

miR-21-3p

miR-146b-5p

miR-210-3p

miR-222-3p

miR-223-3p

miR-517-5p

miR-518a-3p

miR-29a-3p

(-0.066 0.368)

(-0.090 0.243)

(-0.019 0.410)

(-0.083 0.437)

(-0.168 0.307)

(-0.060 0.366)

(-0.020 0.551)

(0.095 0.537)

(0.028 0.493)

(-0.100 0.412)

95% CI

0.173

0.367

0.074

0.181

0.566

0.159

0.068

0.005

0.028

0.232

p-value

0.130

0.026

0.113

0.135

0.080

0.150

0.190

0.262

0.210

0.131

β

(-0.096 0.356)

(-0.151 0.203)

(-0.118 0.344)

(-0.138 0.408)

(-0.172 0.331)

(-0.083 0.382)

(-0.106 0.487)

(0.027 0.496)

(-0.043 0.462)

(-0.139 0.402)

95% CI

Model 2

0.260

0.774

0.337

0.334

0.535

0.207

0.208

0.029

0.103

0.341

p-value

Model 2: Adjusted for gestational age, maternal age at delivery, and pre-pregnancy body-mass index

Model 1: Adjusted for gestational age only

Coefficients and 95% confidence intervals from unadjusted and adjusted logistic regression models showing change in log odds of gestational diabetes mellitus associated with a one-unit increase in logΔΔCt level of candidate miRNAs

0.156

miR-155-5p

β

miR-126-3p

miRNA

Model 1

Coefficients and 95% confidence intervals from logistic regression models examining associations of circulating microRNAs with risk of
gestational diabetes mellitus
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Table 4

Author Manuscript

Author Manuscript

Author Manuscript

0.131

miR-223-3p

(-0.224 0.389)

(-0.217 0.213)

(-0.091 0.468)

(-0.212 0.473)

(-0.312 0.312)

(-0.242 0.294)

(-0.189 0.607)

(-0.088 0.459)

(-0.059 0.611)

(-0.193 0.510)

95% CI

0.597

0.987

0.186

0.456

1.000

0.850

0.304

0.183

0.107

0.376

p-value

0.285

0.142

0.275

0.314

0.321

0.514

0.333

0.467

0.233

0.269

β

(-0.094 0.663)

(-0.154 0.439)

(-0.147 0.698)

(-0.145 0.773)

(-0.114 0.757)

(0.033 0.995)

(-0.128 0.794)

(0.017 0.916)

(-0.133 0.600)

(-0.169 0.707)

95% CI

0.140

0.347

0.202

0.180

0.148

0.036

0.156

0.042

0.213

0.228

p-value

BMI ≥ 25kg/m2
n = 32 (19 GDM cases, 13 controls)

0.401

0.443

0.757

0.525

0.237

0.081

0.679

0.334

0.875

0.691

p-value

Interaction effect*
n = 116

0.315

0.607

0.481

0.536

0.274

0.051

0.716

0.304

0.984

0.883

p-value

Interaction effect**
n = 116

BMI modeled continuously

**

BMI included as overweight yes/no

*

Models were additionally adjusted for gestational age

Coefficients and 95% confidence intervals from logistic regression models showing change in log odds of gestational diabetes mellitus associated with a one-unit increase in log-ΔΔCt level of candidate
miRNAs and p-values from interaction models, stratified by maternal pre-pregnancy body-mass index

0.083

0.000

miR-222-3p

miR-29a-3p

0.026

miR-210-3p

0.189

0.209

miR-146b-5p

-0.002

0.186

miR-21-3p

miR-518a-3p

0.276

miR-155-5p

miR-517-5p

0.158

β

miR-126-3p

miRNA

BMI < 25kg/m2
n = 84 (17 GDM cases, 67 controls)

Coefficients and 95% confidence intervals from logistic regression models examining associations of circulating microRNAs with gestational
diabetes mellitus, stratified by BMI
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Author Manuscript

Author Manuscript

Author Manuscript

0.474

0.665

0.418

0.289

0.218

0.421

0.377

0.073

0.345

miR-21-3p

miR-146b-5p

miR-210-3p

miR-222-3p

miR-223-3p

miR-517-5p

miR-518a-3p

miR-29a-3p

(0.005 0.685)

(-0.156 0.301)

(0.041 0.712)

(0.006 0.836)

(-0.116 0.552)

(-0.026 0.603)

(0.025 0.810)

(0.231 1.099)

(0.121 0.826)

(-0.038 0.724)

95% CI

0.047

0.533

0.028

0.047

0.201

0.072

0.037

0.003

0.008

0.078

p-value

-0.028

0.058

-0.017

-0.034

-0.081

0.046

0.037

0.126

0.035

-0.034

β

(-0.355 0.300)

(-0.200 0.317)

(-0.343 0.309)

(-0.390 0.321)

(-0.457 0.295)

(-0.284 0.377)

(-0.386 0.459)

(-0.170 0.422)

(-0.317 0.388)

(-0.395 0.327)

95% CI

0.869

0.658

0.919

0.850

0.673

0.783

0.866

0.403

0.844

0.854

p-value

Female offspring only
n = 53

0.059

0.977

0.076

0.060

0.130

0.171

0.165

0.020

0.059

0.109

p-value

Interaction effect
n = 114

Two pregnancies with data missing on infant sex were excluded from this analysis

Models were additionally adjusted for gestational age

Coefficients and 95% confidence intervals from sex-stratified logistic regression models showing change in log odds of gestational diabetes mellitus associated with a one-unit increase in log-ΔΔCt level of
candidate miRNAs

0.343

miR-155-5p

β

miR-126-3p

miRNA

Male offspring only
n = 61

Coefficients and 95% confidence intervals from sex-stratified logistic regression models examining associations of circulating microRNAs
with gestational diabetes mellitus
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